Labcorp (LH)
(Delayed Data from NYSE)
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Will LabCorp (LH) Gain on Rising Earnings Estimates?
by Zacks Equity Research
LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
LabCorp (LH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 42.98% and 13.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.
LabCorp (LH) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.
Are Investors Undervaluing LabCorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. ALGN: Which Stock Is the Better Value Option?
Why LabCorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Here's Why LabCorp (LH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain LabCorp (LH) Stock For Now
by Zacks Equity Research
Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).
LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit
by Zacks Equity Research
The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.
Labcorp (LH): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Labcorp (LH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.